Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis
| Autor: | Shuichiro Takahashi, Kunihiko Maeda, Ejiro Omoto, Keiko Aizawa, Mitsumasa Osakabe, Riko Tsumanuma |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Oncology medicine.medical_specialty Cyclophosphamide medicine.medical_treatment Case Report myelofibrosis chemical and pharmacologic phenomena Bone marrow fibrosis Hematopoietic stem cell transplantation 03 medical and health sciences 0302 clinical medicine immune system diseases Fibrosis hemic and lymphatic diseases Internal medicine Internal Medicine medicine Humans Myelofibrosis Aged post-transplantation cyclophosphamide business.industry Myelodysplastic syndromes Hematopoietic Stem Cell Transplantation General Medicine medicine.disease Transplantation surgical procedures operative myelodyspastic syndrome Primary Myelofibrosis haploidentical hematopoietic stem cell transplantation Myelodysplastic Syndromes 030220 oncology & carcinogenesis Stem cell business therapeutics Immunosuppressive Agents 030215 immunology medicine.drug |
| Zdroj: | Internal Medicine |
| ISSN: | 1349-7235 0918-2918 |
| DOI: | 10.2169/internalmedicine.55.6435 |
| Popis: | The prognosis for myelodysplastic syndrome with bone marrow fibrosis (MDS-F) is worse than the prognosis of MDS without fibrosis. Hematopoietic stem cell transplantation (HSCT) is the only curative therapy; however, the indications and the procedures involved in HSCT remain unclear. We herein describe a 69-year-old Japanese man with MDS-F who received haploidentical HSCT and post-transplantation cyclophosphamide. Although the first HSCT resulted in secondary graft failure, the second HSCT using PTCy led to successful engraftment after early improvement in fibrosis. Since the incidence of graft failure is high in myelofibrosis patients, a secondary HSCT using PTCy may be successful if employed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|